AMGEN US Medical Affairs
Amgen brings life-changing therapies to millions of people with inflammatory diseases, with a focus on serving unmet patient needs. For those with debilitating rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, asthma, and other chronic conditions, the suffering and needs are severe. Complex diseases of inflammation have defied simple solutions, and the breadth of inflammatory disease and the burden patients bear is not well understood.
For more than two decades, Amgen has been committed to advancing the science and the understanding around inflammation to address the unmet patient needs that exist and expanding our portfolio. We lead with science through discovery research that is disease-agnostic and biology-first, modality-second.
Our commitment to patients is reflected not only in where we have succeeded, but in where we have failed and opened new doors. Throughout, we have remained dedicated to the principle of leading with science, pursuing where pathways and promising discoveries in inflammation take us. It’s a commitment that extends beyond introducing novel therapies. We are focused on improving the entire patient journey.
Today, with a pipeline that is growing, we move into the future with an advanced understanding of the role that inflammation plays in chronic disease. For Amgen, this opens the door to partnerships and discovery across multiple disease states.
Melina Z. Bayramyan, Pharm.D., Ph.D.
Senior Medical Science Liaison – Inflammation - Rheumatology
Cell: 805-291-9537 Email: email@example.com